Some of the best tech and life science news is just a click away in today’s Bulldog Blog:
- Quintiles has landed a drug commercialization deal in the U.K.
“Almirall and Quintiles have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the UK commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD),” U.K.-based Almirall and Quintiles said Monday.
“After the Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP) issued a positive opinion for the regulatory approval of Almirall’s new LAMA as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD on May 28, 2012, the European Commission finally approved the medicine on July 24.”
- Salix is seeking a meeting with the FDA.
“Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals (NASDAQ: PGNX) today received at approximately 5:00 p.m. ET a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of a Supplemental New Drug Application (sNDA) for RELISTOR (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain,” Salix said Friday. “The CRL requests additional clinical data. Salix and Progenics intend to request an End-of-Review meeting with the Division of Gastroenterology and Inborn Errors Products to better understand the contents of the CRL.”
Salix has requested a meeting about the letter.
- Furiex subsidiary resubmits diabetes drug.
“Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults,” Furiex said Friday. “Takeda anticipates the applications will be reviewed within the next six months. These NDAs were resubmitted in response to a complete response letter Takeda received from the FDA on April 25, 2012.”
- Advanced Animal Diagnostics names new execs.
“Advanced Animal Diagnostics (AAD), a developer of technologies for the rapid diagnosis of farm animal diseases, has added two new employees to lead the company’s sales and marketing efforts. Dr. Francis Adriaens is named Vice President of Marketing and International Sales, and Gary Winter is named Vice President of North America Sales,” the company announced.